Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02221141|
Recruitment Status : Recruiting
First Posted : August 20, 2014
Last Update Posted : February 3, 2021
The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.
Actually the early diagnosis is important because a treatment exists that can prevent future complications.
|Condition or disease|
|Left Ventricular Hypertrophy|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Study Start Date :||December 2013|
|Estimated Primary Completion Date :||December 2022|
|Estimated Study Completion Date :||December 2022|
- Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02221141
|Contact: Laurence Gabriel||+32 81 42 21 11 ext firstname.lastname@example.org|
|Contact: Karine Jourdan||+32 81 42 21 11 ext email@example.com|
|Yvoir, Belgium, 5530|
|Principal Investigator: Laurence Gabriel|